1. Home
  2. NCRA vs RNAZ Comparison

NCRA vs RNAZ Comparison

Compare NCRA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$1.89

Market Cap

3.1M

ML Signal

HOLD

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$2.18

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
RNAZ
Founded
2002
2016
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
3.6M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
NCRA
RNAZ
Price
$1.89
$2.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
305.3K
29.8K
Earning Date
04-15-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,627,944.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$2.24
52 Week High
$3.98
$20.99

Technical Indicators

Market Signals
Indicator
NCRA
RNAZ
Relative Strength Index (RSI) 50.15 27.14
Support Level $0.18 N/A
Resistance Level $2.59 $6.15
Average True Range (ATR) 0.19 0.36
MACD -0.09 -0.02
Stochastic Oscillator 14.12 2.01

Price Performance

Historical Comparison
NCRA
RNAZ

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Share on Social Networks: